Most drugs never get to 60% market share in a category as competitive as Alzheimer’s treatment.
This one did, and now it is applying for a subcutaneous pen that could significantly expand patient access.
You can figure out whether the market dominance, the FDA decision on May 24, and the Q4 earnings beat give you enough reasons to size in before the story gets louder.
Free Resource (Sponsored)
As the financial system continues to evolve, understanding your options matters more than ever.
Reagan Gold Group has created a free Wealth Protection Guide for Americans who want to learn more about protecting retirement savings and exploring alternatives that may offer more stability.
If you want a clearer picture of what FedNow could mean—and what steps may be available to you—this guide is a smart place to start.
Claim your free Wealth Protection Guide now
P.S. It’s a simple, educational resource designed to help you take the next step with confidence.
*Reagan Gold Group does not give financial or tax advice. Price of metals fluctuates and there are no guarantees of performance.
The Q4 Beat That Put This Biotech Back on the Radar
Biogen Inc. (NASDAQ: BIIB) just posted a quarter that cleared out a lot of doubt. EPS came in at $1.99 against a $1.61 estimate.
Revenue hit $2.28 billion against a $2.21 billion estimate. Then management raised 2026 EPS guidance to $15.25 to $16.25, above where consensus was sitting before the print.
BIIB pushed to a 52-week high on earnings day and held most of the move.
A stock that refuses to give back gains after a strong quarter is telling you something about who is in it and why.
EPS $1.99 vs $1.61 estimate: A 23.6% beat on the bottom line. That is not noise.
Revenue $2.28B vs $2.21B estimate: Top line came in clean with room to spare.
2026 guidance $15.25 to $16.25 EPS: Management raised the bar after the beat. That combination is rare.
New products now account for one-third of total revenue: Leqembi, Skyclarys, Zurzuvae, and Qalsody grew 6% year over year in Q4 and are gaining more weight each quarter.
The beat gave the stock a pulse. The hold afterward is what makes it worth paying attention to.
Action: On the April 30 call, if Leqembi net sales come in above $200M and new product revenue keeps climbing, add immediately.
A miss below $150M with no upward revision tells you the growth engine stalled, and you reduce the same day.
Step-by-Step (Sponsored)
Washington has introduced a change that could affect how retirement investors think about portfolio diversification.
As interest in gold continues to grow, many Americans are asking whether physical precious metals can play a role inside an eligible retirement account.
The answer may be yes — and for some investors, that option may already be available today.
Our free guide explains how physical gold may be purchased through certain retirement accounts, including eligible 401(k)s and IRAs.
Leqembi Owns the Alzheimer’s Market, and a Pen Is Coming to Grow It Further
Leqembi holds over 60% of the anti-amyloid Alzheimer’s treatment market. That is the current share, not a target.
Building that kind of lead in a new drug class takes real clinical differentiation, and Leqembi has it.
A subcutaneous pen formulation is now under FDA priority review with a decision date of May 24. The current version requires an IV infusion every two weeks.
A pen means patients administer it at home, which removes a major barrier for physicians and patients alike.
More convenience equals more uptake, and more uptake from a drug already at 60% share is a real revenue driver.
60% anti-amyloid market share: Dominant position in a category that is still in early adoption. Most patients eligible for treatment have not started yet.
Subcutaneous pen PDUFA date May 24: FDA priority review is a signal the agency sees clinical value. Approval could meaningfully accelerate new patient starts.
Home administration removes a major barrier: Infusion centers are a real friction point for elderly patients. A self-administered pen changes the prescribing conversation entirely.
If the pen gets approved on May 24, you want to already be in position. Waiting for the announcement means buying after the market has already moved.
Action: Put on 20% of your position now before May 24. Pen approved, add another 20% that day.
Complete response letter or delay, hold what you have, and reassess on the next quarterly print. Do not sell into the reaction.
Don’t Miss Out (Sponsored)
Many investment banks just raised their targets to $6,000/oz... mere weeks after predicting $5,000.
Even Jim Cramer now admits to being a "gold bug."
But nearly everyone is missing an even bigger story: the absolute best way to invest in gold right now.
The New Product Engine Is Replacing Revenue the Legacy Drugs Are Losing
Biogen’s older MS drugs are declining at a mid-teens rate annually due to biosimilar competition. That pressure is not going away.
The important thing is that new products are filling the gap faster than the legacy decline is creating it.
New products now make up roughly one third of total revenue and grew 6% year over year in Q4. Each quarter that percentage climbs, the legacy drag matters less.
The transition is clearly in motion.
Legacy MS revenue declining mid-teens annually: Biosimilar pressure is real and ongoing. This is a known headwind, not a surprise.
The legacy decline is priced in. The new product ramp is where the opportunity sits for you.
Action: On the April 30 call, if new products cross 35% of total revenue, add 15% to your position.
New products stalling below 30% while legacy worsens means the transition is losing steam, and you cut exposure by half.
How BIIB Stacks Up Against Its Biotech Peers Right Now
Most large-cap biotechs have had a rough eighteen months. BIIB is up 33% over the trailing year, while Amgen is up around 15% over the same stretch.
That gap does not happen by accident.
BIIB has a market-leading drug, an earnings beat with a guidance raise, and a pipeline catalyst on a specific date.
Peers dealing with patent cliffs or binary readouts without that combination do not have the same near-term clarity.
33% trailing-year gain vs roughly 15% for Amgen: Outperforming the peer group with room to extend.
Earnings beat came with a guidance raise: Most peers beat or raised. Doing both in the same print is less common.
May 24 is a specific date with a binary outcome: That kind of calendar clarity is rare and gives you a defined window to position around.
Relative strength in a struggling sector with a specific catalyst date ahead is the combination you want.
Action: BIIB holds its relative strength lead over Amgen for ten straight sessions, add another 10%.
A large-cap peer starts outperforming BIIB on a rolling five-day basis; rotate a third of your exposure into the stronger name rather than waiting for a catch-up.
The Pipeline Beyond Leqembi Is Where the Next Leg Could Come From
Leqembi is the flagship, but the pipeline has more coming. BIIB080 targets tau in Alzheimer’s, a different mechanism than amyloid, with data due mid-2026.
BIIB122 targets Parkinson’s disease, also in mid-2026. Litifilimab is in Phase 3 for lupus with a readout by end of 2026.
These are late-stage programs with defined timelines, not early speculation. Anyone reading out positively adds a new revenue stream to a business that already has a strong base.
BIIB080 tau data mid-2026: Complementary to Leqembi in Alzheimer’s. Positive data could expand the treatment addressable market significantly.
BIIB122 Parkinson’s data mid-2026: Large patient population with limited disease-modifying options currently available.
Three catalysts in the next twelve months: That cadence keeps the story active well beyond the May 24 pen decision.
You are not dependent on any single catalyst. The pipeline gives you multiple shots over the next twelve months.
Action: Mark BIIB080 and BIIB122 data dates mid-2026 in your calendar now.
Size up 10% in the two weeks before each readout and trim back to your base position immediately after, regardless of the result.
Binary catalysts reward being early, not reacting fast.
Poll: What’s the most irrational thing people do with money?
The Risks Are Specific, and That Makes Them Manageable
The biggest risk is not the business. It is the FDA. A complete response letter on May 24 removes the nearest catalyst and likely takes the stock down on the day.
What makes it manageable is that a pen rejection does not change the Leqembi IV story or the market share. The base business holds even if the near-term catalyst disappoints.
The second risk is that the legacy MS decline is accelerating faster than new products can offset. Watch the revenue mix on every quarterly print.
New products growing faster than legacy products means the story stays intact.
Pen rejection on May 24 is a binary downside event: Stock could drop 10% or more on a complete response letter. That is the primary risk to size around.
Legacy MS biosimilar erosion could accelerate: If Tysabri or Vumerity face new biosimilar entrants, the decline rate steepens and puts more pressure on new products to compensate.
Pipeline readouts are never guaranteed: BIIB080, BIIB122, and litifilimab all carry clinical risk. Any one of them failing changes the pipeline narrative meaningfully.
Clear risks with defined triggers are better than hidden ones. You know exactly what to watch for.
Action: Trim 15% as a hedge against a pen rejection. FDA approves, rebuild that 15% the same day.
Complete response letter issued, hold the trimmed position, and do not sell further unless Leqembi also disappoints on April 30.
One setback is manageable. Two together changes the thesis.
Final Word: The Market Share Is Real, and the Calendar Is on Your Side
Biogen is a transition story that is further along than most give it credit for. Leqembi owns 60% of its market. New products are growing.
The balance sheet is clean. The 2026 guidance was raised after a strong beat. A specific catalyst lands in just over two months.
The legacy headwind is real, and the pipeline carries clinical risk.
But a dominant Alzheimer’s franchise, a near-term FDA decision, and three pipeline readouts over the next year give you more ways to win than lose.
Watch April 30, position before May 24, and use the pipeline calendar as your map.
Setup Scorecard
Entry Window: Current levels. Position before May 24, not after.
Catalyst Watch: April 30 Q1 print, May 24 pen PDUFA, BIIB080 and BIIB122 data mid-2026, litifilimab end of 2026.
Upside Setup: Pen approval plus Leqembi share gains plus any pipeline readout creates multiple legs of upside.
Downside Cushion: $4.2B cash, 60% market share in a growing category, and raised guidance limit how bad one setback gets.
What Moves It Next: Leqembi net sales, new product revenue percentage, and the May 24 FDA decision.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any value names you want me to check out.
Best Regards,
—Noah Zelvis
Undervalued Edge
